Abstract
Acute administration of mecamylamine, a centrally active nicotinic cholinergic agonist, has been shown to increase amount of smoking as indicated by smoking topography (e.g., puff rate, puff duration), expired carbon monoxide changes, and other inferential measures. In the present study, subjects showed significantly greater increases in plasma nicotine following smoking of two high-nicotine research cigarettes when pretreated with mecamylamine than when pretreated with placebo, even though no significant differences in puff volume or puff number were detected. Interestingly, none of our subjects reported nausea, although some achieved plasma nicotine levels at which nausea would typically be expected. We attribute the observed increases in nicotine intake to compensatory behavior designed to overcome mecamylamine's blocking effects.
This is a preview of subscription content, log in via an institution to check access.
References
Barrass BC, Blackburn JW, Brinblecombe RW, Rich P (1969) Modification of nicotine toxicity by pretreatment with different drugs. Biochem Pharmacol 18:2145–2152
Domino EF (1973) Neuropsychopharmacology of nicotine and tobacco smoking. In: Dunn WL, Jr. (ed) Smoking behavior: motives and incentives. Winston, Washington DC, pp 5–31
Goldberg SR, Spealman RD, Risner MD, Henningfield JE (1983) Control of behavior by intravenous nicotine injection in laboratory animals. Pharmacol Biochem Behav 19:1011–1020
Henningfield JE (1984) Pharmacologic basis and treatment of cigarette smoking. J Clin Psychiatry 45 [12, sec. 2]:24–34
Herning RI, Jones RT, Benowitz NL, Mines AH (1983) How a cigarette is smoked determines nicotine blood levels. Clin. Pharmacol Ther 33:84–90
Jarvik ME (1973) Further observations on nicotine as the reinforcing agent in smoking. In: Dunn WL (ed) Smoking behavior: motives and incentives. Winston, Washington DC, pp 33–49
Nemeth-Coslett R, Henningfield JE, O'Keeffe MK, Griffiths RR (1986) Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology 88:420–425
Pomerleau OF, Fertig JB, Shanahan SO (1983) Nicotine dependence in cigarette smoking: An empirically-based, multivariate model. Pharmacol Biochem Behav 19:291–299
Pomerleau OF, Turk DC, Fertig JB (1984) The effects of cigarette smoking on pain and anxiety. Addict Behav 9:265–271
Seyler LE Jr., Pomerleau OF, Fertig JB, Hunt D, Parker K (1986) Pituitary hormone response to cigarette smoking. Pharmacol Biochem Behav 24:159–162
Spealman RD, Goldberg RD (1982) Maintenance of schedule-controlled behavior by intravenous injections of nicotine in squirrel monkeys. J Pharmacol Exp Ther 223:402–408
Stolerman IP, Goldfarb T, Fink R, Jarvik ME (1973) Influencing cigarette smoking with nicotine antagonists. Psychopharmacologia 28:217–259
Taylor P (1980) Ganglionic stimulating and blocking agents. In: Gilman AG, Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics (6th ed). MacMillan, New York, pp 211–219
Tennant FS, Tarver AL, Rawson RA (1984) Clinical evaluation of mecamylamine for withdrawal from nicotine dependence. In: Harris LS (ed) Problems of drug dependence. National Institute on Drug Abuse, Research Monograph, Volume 49, (ADM) 84-1316. Government Printing Office, Washington DC
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pomerleau, C.S., Pomerleau, O.F. & Majchrzak, M.J. Mecamylamine pretreatment increases subsequent nicotine self-administration as indicated by changes in plasma nicotine level. Psychopharmacology 91, 391–393 (1987). https://doi.org/10.1007/BF00518198
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00518198